July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.
Author Affiliations & Notes
  • Charles Hennings
    Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
  • Mira Deshmukh
    Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
  • Vuong Nguyen
    Macula Research Group, Save Sight and Eye Health Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Martin Harris
    Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
  • Riaz Asaria
    Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
  • Daniel Barthelmes
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
    Macula Research Group, Save Sight and Eye Health Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Mark C Gillies
    Macula Research Group, Save Sight and Eye Health Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Hemal Mehta
    Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
    Macula Research Group, Save Sight and Eye Health Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Charles Hennings, Bayer (F); Mira Deshmukh, None; Vuong Nguyen, None; Martin Harris, Allergan (F), Bayer (F), Novartis (F); Riaz Asaria, Allergan (F), Almera Sciences (F), Bayer (F), Novartis (F); Daniel Barthelmes, Bayer (F), Bayer (C), Novartis (F), Novartis (C); Mark Gillies, Allergan (F), Allergan (C), Bayer (C), Bayer (F), Novartis (F), Novartis (C); Hemal Mehta, Alimera Sciences (C), Allergan (F), Allergan (C), Bayer (F), Bayer (C), Heidelberg (F), Novartis (F), Novartis (C)
  • Footnotes
    Support  Bayer are proud to support an audit fellow at the Royal Free London NHS Foundation Trust.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3616. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Charles Hennings, Mira Deshmukh, Vuong Nguyen, Martin Harris, Riaz Asaria, Daniel Barthelmes, Mark C Gillies, Hemal Mehta; Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3616.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The European license of aflibercept for center-involving diabetic macular edema (DME) is based on the VIVID and VISTA clinical trials. In the UK, NICE does not routinely fund this treatment unless central macular thickness (CMT) is >400 µm. We wished to identify outcomes for patients in a UK real-world setting compared with seminal phase III clinical trials.

Methods : We performed a prospective, dual-center observational study of all anti-VEGF treatment-naïve eyes receiving aflibercept for at least 24 weeks at the Royal Free London NHS Foundation Trust (RFLNFT). Fight Retinal Blindness! software was used to record real-world outcomes including distance visual acuity (VA) and central subfield thickness (CST). P-values were obtained using paired t-tests.

Results : There were 33 eyes from 27 patients. The mean (SD) VA at the first injection was 64.1 (9.3) LogMAR letters. At 24 weeks, after a median of 5 (range 3-6) injections, the mean (SD) VA was 67.4 (9.1) letters, an increase of 3.3 (95% CI: -0.4, 7.0; P = 0.08) letters. The percentage of eyes gaining 15 letters was 18% (6 eyes) and losing 15 letters was 3% (1 eye). The mean (SD) CST at the first injection was 416 (79) µm. At 24 weeks, this reduced to 290 (86) µm, a decrease of 126 (95% CI: -167, -85; P<0.001) µm. Twelve eyes had previous macular laser. Compared with the VIVID and VISTA clinical trials, baseline VA and CST was better in our cohort (Table 1).

The percentage of eyes with legal driving vision (≥70 letters) was 53% when CST was first >300 µm, 36% (12 eyes) at time of first injection and 45% (15 eyes) after 24 weeks. The median (Q1,Q3) delay between CST >300 µm and first injection of aflibercept as per NICE guidance was 328 days (57,629) days. This delay was associated with a mean VA loss of 5.6 (95% CI: -9.3, -1.8; P=0.005) letters.

Conclusions : Patients in the real-world receiving aflibercept for DME as per NICE guidance can achieve some visual improvement after 24 weeks. The visual and anatomical improvement was not as great as the VIVID and VISTA trials. This likely relates to less room for improvement due to better baseline VA and CST in our cohort. Delay in initiating treatment from diagnosis of center-involving DME >300 µm until CMT >400 µm was associated with significant visual morbidity.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Table 1: Baseline and mean change at 24 weeks for visual acuity and central subfield thickness.

Table 1: Baseline and mean change at 24 weeks for visual acuity and central subfield thickness.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×